Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prime Medicine (PRME) Income towards Parent Company (2021 - 2025)

Historic Income towards Parent Company for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$52.8 million.

  • Prime Medicine's Income towards Parent Company fell 59.79% to -$52.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$199.6 million, marking a year-over-year increase of 896.7%. This contributed to the annual value of -$195.9 million for FY2024, which is 113.61% up from last year.
  • According to the latest figures from Q3 2025, Prime Medicine's Income towards Parent Company is -$52.8 million, which was down 59.79% from -$52.6 million recorded in Q2 2025.
  • In the past 5 years, Prime Medicine's Income towards Parent Company ranged from a high of -$16.4 million in Q3 2021 and a low of -$65.6 million during Q4 2023
  • Moreover, its 5-year median value for Income towards Parent Company was -$45.8 million (2024), whereas its average is -$44.3 million.
  • Over the last 5 years, Prime Medicine's Income towards Parent Company had its largest YoY gain of 3754.39% in 2022, and its largest YoY loss of 7883.26% in 2022.
  • Prime Medicine's Income towards Parent Company (Quarter) stood at -$62.9 million in 2021, then soared by 37.54% to -$39.3 million in 2022, then crashed by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then fell by 24.97% to -$52.8 million in 2025.
  • Its Income towards Parent Company was -$52.8 million in Q3 2025, compared to -$52.6 million in Q2 2025 and -$51.9 million in Q1 2025.